
2007 had its up and downs
The year had a promising start when Belgian drug developer Movetis raised EUR49m in a financing round led by Sofinnova Partners and Life Sciences Partners. Bridgepoint acquired educational publisher Wolters Kluwer Education in March for EUR774m, while Lion Capital bought general merchandise retailer Hema from retail group Maxeda in a deal reported to be worth EUR1.1bn.
Then the credit squeeze came, forcing Kohlberg Kravis Roberts & Co to cancel its plans to raise EUR1bn of loans to refinance Maxeda. Mid-market players in the region, however, claimed that the market troubles hardly affected them, thanks to modest levels of leveraging. Even larger deals, such as CVC's EUR800m acquisition of Taminco, could be completed despite the turmoil. Two large de-listings came as the dust started to settle: CVC de-listed chemicals distributor Univar for EUR1.52bn, and Candover is to take Stork private for EUR1.5bn after prolonged negotiations with the company's shareholders.
Although large transactions involving international players make the headlines, the bulk of the industry activity continues to stem from mid-market buyouts and venture investments. Most of these deals do not get the public attention they deserve, but they have and will continue to make a difference.
Yours truly,
Irmak Bademli
Benelux editor, unquote"
Tel: +44 20 7004 7475
irmak.bademli@incisivemedia.com.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater